Buchumschlag

Letter: Rifaximin Versus Low FODMAP Diet in IBS : What the Primary Endpoint Does Not Tell Us

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Luisa Bertin, Edoardo Vincenzo Savarino
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Letter: Gastroparesis in Lung Transplantation: Time to Reframe and Standardise Post‐Transplant Foregut Motility Evaluation
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis. Authors' Reply
von: Pierfrancesco Visaggi, et al.
Veröffentlicht: (2026)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
von: Brigida Barberio, et al.
Veröffentlicht: (2026)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease
von: Javier Chahuán, et al.
Veröffentlicht: (2026)

Letter on ‘Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis ( EndoFOD )—A Randomised, Controlled Crossover Feeding Study’
von: Wancheng Zhao, et al.
Veröffentlicht: (2025)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS
von: Cecilia Katzenstein, et al.
Veröffentlicht: (2024)

Letter: Interpreting Faecal SCFA Enrichment in IBS‐D—Metabolic Signal or Transit‐Related Marker?
von: Longying Zhang, et al.
Veröffentlicht: (2026)

Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply
von: E. Coss‐Adame, et al.
Veröffentlicht: (2026)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
von: Anthony O'Connor, et al.
Veröffentlicht: (2024)

Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS‐BAD
von: Camille Lupianez‐Merly, et al.
Veröffentlicht: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
von: Liang Jiao, et al.
Veröffentlicht: (2026)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
von: Alice S. Day, et al.
Veröffentlicht: (2025)

Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study
von: Francesco Calabrese, et al.
Veröffentlicht: (2024)

Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'
von: Francesco Calabrese, et al.
Veröffentlicht: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
von: Sanjay K. Murthy
Veröffentlicht: (2026)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
von: Iris Barth, et al.
Veröffentlicht: (2024)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
von: Sofia Tsitsou, et al.
Veröffentlicht: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
von: Muhammad Abubakr, et al.
Veröffentlicht: (2025)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis
von: Saverio Pochesci, et al.
Veröffentlicht: (2026)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
von: Peter J. Kahrilas, et al.
Veröffentlicht: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
von: Leyu Zhou, et al.
Veröffentlicht: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
von: Qiang Hu, et al.
Veröffentlicht: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
von: Ao Gao, et al.
Veröffentlicht: (2026)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
von: Elisa Pinto, et al.
Veröffentlicht: (2026)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
von: Yuanyan Sun, et al.
Veröffentlicht: (2026)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2026)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
von: Yewan Park, et al.
Veröffentlicht: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
von: Bo Li, et al.
Veröffentlicht: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
von: Yi Pei, et al.
Veröffentlicht: (2025)

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract
von: Michael Camilleri, et al.
Veröffentlicht: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
von: Jia‐Yong Su, et al.
Veröffentlicht: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
von: Conrado Fernandez‐Rodriguez, et al.
Veröffentlicht: (2024)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
von: Isabella Lurje, et al.
Veröffentlicht: (2025)

Letter: Intestinal Ultrasound‐Prioritising Progress
von: Kacie H. Denton, et al.
Veröffentlicht: (2026)

Letter: Irritable bowel syndrome and antibiotics
von: George F. Longstreth
Veröffentlicht: (2024)